全球智能吸入器市场-2022-2029

市场动态

全球智能吸入器市场由空气污染引起的哮喘和吸烟习惯的迅速增加、COPD 患病率增加导致对智能吸入器的需求增加、各种具有成本效益的新产品的推出以及新技术的发展推动。由于若干因素，例如进步，它正在增长。

哮喘发病率的上升和各种新技术的进步预计将推动市场的增长。

由于哮喘、空气污染导致的慢性阻塞性肺病和吸烟习惯激增的患病率上升，对智能吸入器的需求不断增长将推动市场。根据 ODPHP 疾病预防和健康促进办公室的数据，预计 2020 年将有 2500 万哮喘患者来自美国，其中 1480 万人将被诊断出患有 COPD，最常见于儿童和老年人，超过 3.39 亿人在世界范围内，它是一种常见疾病。由于吸烟习惯的激增和世界上空气污染的增加，COPD 作为一种非传染性疾病正在上升。智能吸入器可以通过移动应用程序和网络平台通过无线技术连接，为医生收集有关每种药物使用情况和信息的关键数据。

FDA 批准的数量有所增加，并且推出了新的创新技术，用于监测和跟踪支持蓝牙和基于应用程序的哮喘和其他呼吸系统疾病的智能吸入器。 2020 年 1 月 23 日，美国食品药品监督管理局 (FDA) 批准了 Cognita Labs，称为 CapMedic Smart Inhaler Caps。该设备可以通过反馈机制跟踪患者信号，并为正确使用吸入器提供指导。

与这些智能吸入器相关的高成本预计将阻碍市场增长。

全球智能吸入器市场可能受制于这些智能吸入器的高成本。由于这些吸入器保留自己的数据记录，数据滥用的可能性甚至数据洩露的可能性将限制市场增长。

行业分析

全球智能吸入器市场基于波特五力、监管分析、供应链分析和价格分析等各种行业因素对市场进行了深入分析。

内容

第一章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

• 市场影响因素
  • 驱动程序
    • 哮喘和慢性阻塞性肺病的发病率不断上升
    • 技术进步的增加
  • 限制因素
    • 智能吸入器成本高
  • 商机
  • 影响分析

第五章行业分析

• 波特五力分析
• 监管分析
• 供应链分析
• 定价分析

第 6 章按类型

• 智能吸入器行业干粉吸入器
• 鼻腔吸入器
• 计量吸入器
• 其他

第 7 章按销售渠道

• 零售药房
• 呼吸中心
• 医院药房
• 在线药店

第8章按功效和作用

• 支气管哮喘
• 慢性阻塞性肺病 (COPD)
• 其他

第 9 章按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第 10 章竞争格局

• 主要发展和战略
• 公司份额分析
• 按类型进行基准测试
• 值得关注的重点公司列表

第 11 章公司简介

• Teva Pharmaceuticals
  • 公司概况
  • 按类型和描述划分的投资组合
  • 主要亮点
  • 财务摘要
• Novartis
• Vectura Group
• MannKind
• Respironics
• Orion Pharm
• Hovione
• AstraZeneca
• OPKO Health Inc
• Boehringer-Ingelheim
• 3M
• BreatheSuite Inc
• Sunovion Pharmaceuticals
• Aristopharma
• GlaxoSmithKline
• Cohero Health LLC

第12章 全球智能吸入器市场-DataM

Market Overview

Smart Inhalers Market size was valued US$ 167.40 million in 2021 and is estimated to reach US$ 995.38 million by 2029, growing at a CAGR of 26.1% during the forecast period (2022-2029).

Smart inhalers are connected to multiple devices like mobiles, laptops, personal computers, etc., to monitor the patient's information related to respiratory diseases. Smart inhalers can be connected through mobile induction which helps patients and healthcare providers monitor important information like medication schedules and dosage reminders. Inhalers use Bluetooth technology to detect, remind patients about the inhaler's use and medication timing to take care of patients. Smart inhalers can improve patients' health to provide crucial for asthma and COPD information to keep their condition under control.

Market Dynamics

The global smart inhalers market is growing due to several factors such as rising demand for smart inhalers due to the increasing prevalence of Asthma, COPD due to a surge in air pollution and smoking habits, various new cost-effective product launches and novel technological advances.

Rising incidence of Asthma and various new technological advancements are expected to drive market growth.

The rising demand for smart inhalers drives the market due to the increasing prevalence of Asthma, COPD due to a surge in air pollution and smoking habits. According to the ODPHP Office of Disease Prevention and Health Promotion, in 2020, the estimated Asthma patients were over 339 million people globally among which 25 million are from United States, 14.8 million are diagnosed with COPD these are the most common disease among children and the geriatric population. This is a growing non-communicable disease owing to a surge in smoking habits and rising global air pollution. Smart inhalers can be connected via wireless technology through the mobile app & web platform, providing crucial for asthma collects data for doctors about each drug usage and information.

There is a rise in the launching and FDA clearance of new innovative technology implemented with patient monitoring and tracking Bluetooth enabled and app-based smart inhalers for Asthma and other respiratory diseases. On 23rd Jan 2020, the U.S. Food and Drugs Administration (FDA) has been cleared the smart inhaler cap from Cognita Labs, Known as CapMedic. The device can track patients' signals with a feedback mechanism and provide guidance to use inhalers correctly.

High cost associated with these smart inhalers is expected to hamper the market growth.

The global smart inhalers market can be restrained by the high cost of these smart inhalers. These inhalers keep the data records with themselves so the data can be misused and even there are chances of data leakage hence limiting the market growth.

Industry Analysis

The global smart inhalers market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis.

Segment Analysis

Type segment is expected to hold the largest market share in global smart inhalers market

The global smart inhalers market is segmented based on type, distribution channel, Indication, and region.

The global smart inhalers market is bifurcated into dry powder inhalers, nasal inhalers, metered-dose inhalers, and others in terms of types. This metered dose inhalers segment has the highest share due to the increasing new technology-based launching of smart inhalers by prominent players like Teva Pharmaceuticals, Novartis, Vectura Group, MannKind, Respirices, and Lupin. For instance, on 22nd Nov 2019, Lupin Company launched ADHERE as a smart device for metered-dose inhalers. This inhaler has the facility to connect with smartphone Indication via Bluetooth. It is a reusable smart device that tracks and sends reminders to the patient's daily medication usage and consumption patterns via smartphone through the "MyAdhero" app.

Similarly, dry powder inhalers and nasal inhalers are also growing faster due to a surge in the prevalence of respiratory diseases like Asthma, COPD, and many others across the globe with the population's surgeon. Dry powder inhalers are growing faster due to rising awareness of their advantages, like avoiding drug irritation and easy use.

Depending upon indication, the global smart inhalers market is divided into Asthma and chronic obstructive pulmonary disease (COPD). Among this Asthma, the segment has the largest share due to the increasing prevalence of Asthma disease around the globe due to the surge in people's smoking habits.

Similarly, the chronic obstructive pulmonary disease (COPD) segment is also growing faster with a surge in the global COPD disease burden. This is primarily due to increasing air pollution worldwide which propels this segmental growth during the forecast period.

The global smart inhalers are segmented into retail pharmacies, respiratory care centers, hospital pharmacies, and online pharmacies depending on the distribution channels. Among these, the retail pharmacies segment had the highest market share in 2019. This growth is anticipated due to the rise in pharmacies' retail shops, increasing awareness about non-communication diseases like Asthma, COPD, etc.

Similarly, the online pharmacies segment has the highest market share due to increased healthcare online consulting trends with the surge in online sales through portals like Flipkart, Amazon, etc. Furthermore, respiratory care centers and hospital pharmacies are also growing faster due to the increasing number of hospitals and respiratory centers worldwide, with the surge in the prevalence of respiratory diseases due to a surge in the global air pollution due to smoke.

Geographical Analysis

North America region holds the largest market share in the global smart inhalers market

By region, the global smart inhalers market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global smart inhalers market and expected to grow at the highest CAGR during the forecasted period due to the presence of advanced technology adoption and surge in prevalence of respiratory diseases followed by the European region. According to the American Lung Association, there are around 12.5 million people diagnosed with COPD. Estimated around 6.1 million children under 18 years were affected due to Asthma in North America, followed by Europe. This propels the smart inhalers demand in this region with increasing the number of leading players and the presence of advanced technology in this region. According to World Health Organisation, in 2019 Chronic pulmonary disease caused 3.23 million deaths making it third leading cause of worldwide deaths.

The Asia-Pacific region is expected to have positive market growth due to the growing prevalence of Asthma due to surging in smoking habits and increasing air pollution. Forum of International Respiratory Societies in 2022, has reported more than 65 million people are suffering from COPD, 3 million people dies every year with COPD and 1.6 million people dies from lung cancer every year. In China there are 300 million smokers with annual consumption of 2 trillion cigarettes, the highest tobacco consuming nation with a record of a single person dies every 30 seconds from tobacco use. Furthermore, increasing the adoption of advanced technology to prevent such respiratory disorders with smart inhalers with the surge in population will boost the market demand over the forecasted period.

Competitive Landscape

The global smart inhalers market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition Teva Pharmaceuticals, Novartis, Vectura Group, MannKind, Respironics, Orion Pharm, Hovione, AstraZeneca, OPKO Health Inc, Boehringer-Ingelheim, 3M, BreatheSuite Inc, Sunovion Pharmaceuticals, Aristopharma, GlaxoSmithKline and Cohero Health LLC are the leading market players with significant market share.

Major players receive new technology sensors and app-based advanced smart inhalers for curing respiratory diseases in the healthcare industry. For instance, on 22nd Jan 2020, BreatheSuite Inc Company had launched the world's first smart inhaler, which the FDA approved. BreatheSuite Inc's smart inhaler, named ProAir Digihaler, was launched in the United States market through an sNDA Indication. The ProAir Digihaler has a sensor used in real-time tracking, monitoring the patients, and collecting the syncs data through a mobile app.

Companies are entering into collaborations, acquisitions, mergers, and licensing for increasing their market penetration. For instance, on 28th January 2020, Aptar Pharma, a leading drug delivery services and active packaging solutions Company has been partnered with Lupin Limited to launch India's first smart connected device for metered-dose inhalers (MDI) called ADHERO.

Key Companies to Watch

Teva Pharmaceuticals:

Overview: Teva Pharmaceuticals is Israel-based multinational pharmaceutical company, founded in 1901 and headquartered in Tel Aviv, Israel. It specializes in generic drugs (primary), active pharmaceutical ingredients and proprietary pharmaceuticals.

Product Portfolio:

AirDuo Digihaler: AirDuo Digihaler (fluticasone propionate and salmeterol) inhalation powder is used for asthma patient's treatment aged 12 years and older. It is only for patients uncontrolled on an inhaled corticosteroid (ICS).

Key Developments: In May 2022, Teva pharmaceuticals announced novel findings on the basis of latest clinical thresholds on SABA short acting beta agonist use that is useful for patients with asthma and potential of ProAir Digihaler inhalation powder (digital inhaler).

The global smart inhalers market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. Rising Incidence of Asthma and COPD
    • 4.1.1.2. Increasing technological advancements
  • 4.1.2. Restraints:
    • 4.1.2.1. High cost of smart inhalers
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Regulatory Analysis
• 5.3. Supply Chain Analysis
• 5.4. Pricing Analysis

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
  • 6.1.2. Market Attractiveness Index, By Type Segment
• 6.2. Dry Powder Inhalers for the Smart Inhalers industry
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 6.3. Nasal Inhalers
• 6.4. Metered Dose Inhalers
• 6.5. Others

7. By Distribution Channel

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 7.1.2. Market Attractiveness Index, By Distribution Channel Segment
• 7.2. Retail Pharmacies
  • 7.2.1.1. Introduction
  • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Respiratory Care Centers
• 7.4. Hospital Pharmacies
• 7.5. Online Pharmacies

8. By Indication

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Segment
  • 8.1.2. Market Attractiveness Index, By Indication Segment
• 8.2. Asthma
  • 8.2.1.1. Introduction
  • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Chronic obstructive pulmonary disease (COPD)
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. Australia
    • 9.5.6.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

10. Competitive Landscape

• 10.1. Key Developments and Strategies
• 10.2. Company Share Analysis
• 10.3. Types Benchmarking
• 10.4. List of Key Companies to Watch

11. Company Profiles

• 11.1. Teva Pharmaceuticals
  • 11.1.1. Company Overview
  • 11.1.2. Type Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Novartis
• 11.3. Vectura Group
• 11.4. MannKind
• 11.5. Respironics
• 11.6. Orion Pharm
• 11.7. Hovione
• 11.8. AstraZeneca
• 11.9. OPKO Health Inc
• 11.10. Boehringer-Ingelheim
• 11.11. 3M
• 11.12. BreatheSuite Inc
• 11.13. Sunovion Pharmaceuticals
• 11.14. Aristopharma
• 11.15. GlaxoSmithKline
• 11.16. Cohero Health LLC

LIST NOT EXHAUSTIVE

12. Global Smart Inhalers Market - DataM

• 12.1. Appendix
• 12.2. About Us and Indication
• 12.3. Contact Us